Cyclooxygenase-2 selective inhibitors

Drugs of Today

Volumn 35, Issue 7, 1999, Pages 487-496

  Cannon, Grant W ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FENOPROFEN; FLUCONAZOLE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LITHIUM; MEFENAMIC ACID; NAPROXEN; NIMESULIDE; OXAPROZIN; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULINDAC; TOLMETIN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME BINDING; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; FEMALE INFERTILITY; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOARTHRITIS; PAIN; REVIEW; RHEUMATOID ARTHRITIS; TERATOGENESIS; THROMBOSIS;

EID: 0032883126     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.7.548261     Document Type: Review

References (43)

1. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971, 231: 232-5.
2. Bjorkman, D.J. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998, 105(1B): 8-12S.
3. Fenner, H. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic andpharmacodynamic profiles. Semin Arthritis Rheum 1997, 26: 28-33.
4. Vane, J.R., Botting, R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104(4A): 2-22S.
5. Vane, J.R., Botting, R.M. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997, 26: 2-10.
6. Simon, L.S. Biology and toxic effects of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1998, 10: 153-8.
7. Fries, J.F., Williams, C.A., Bloch, D.A. et al. NSAID associated gastropathy: Incidence and risk factor models. Am J Med 1991, 912: 213-21.
8. Griffen, M.R., Piper, J.M., Daugherty, J.R. et al. NSAID use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114: 257-63.
9. Garell, S., Matarese, R.A. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine 1984, 63: 163-81.
10. McQueen, E.G., Facoory, B., Faed, J.M. Nonsteroidal anti-inflammatory drugs and platelet function. NZ Med J 1986, 99: 358-60.
11. Needleman, P., Isakson, P.C. The discovery and function of COX-2. J Rheumatol 1997, 24(Suppl. 49): 6-8.
12. Breder, C.D., DeWitt, D.L., Kraig, R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995, 355: 196-315.
13. Crofford, J. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997, 24: 1519.
14. Yamagata, H., Andreasson, K.I., Kaufmann, W.E. et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activities and glucocorticoids. Neuron 1993, 11: 371-86.
15. Jouzeau, J.Y., Terlain, B., Abid, A., Nedelec, E., Netter, P. Cyclo-oxygenase isoenzymes. Drugs 1997, 53: 563-82.
16. Maclouf, J., Folco, G., Patrono, C. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998, 79: 691-705.
17. Wallace, J.L., Bak, A., McKnight, W., Asfaha, S., Sharkey, K.A., MacNaughton, W.K. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Gastroenterology 1998, 115: 101-9.
18. Singer, I.I., Kawka, D.W., Schloemann, S., Tessner, T., Riehl, T., Stenson, W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998, 115: 297-306.
19. Ukawa, H., Yamakuni, H., Kato, S., Takeuchi, K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci 1998, 43: 2003-11.
20. Sorli, C.H., Zhang, H., Armstrong, M.B. et al. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci USA 1998, 95: 1788-93.
21. Kawai, S., Nishida, S., Kato, M. et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998, 347: 87-94.
22. Hawkey, C.J. COX-2 inhibitors. Lancet 1999, 353: 307-14.
23. Frolich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. TIPS 1997, 18: 30-4.
24. Cryer, B., Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104: 413-21.
25. Bolten, W.W. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998, 25 (Suppl. 51): 2-7.
26. Package insert Celecoxib (Celebrex). G.D. Searle & Co. Chicago, IL 1998.
27. Karim, A., Tolber, D., Peirgies, A. et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. Arthritis Rheum 1998, 41(Suppl.): S315.
28. Ehrich, E., Schnitzer, T., Kivitz, A. et al. MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 1997, 40(Suppl.): S85.
29. Lanza, F.L., Callison, D.A., Hubbard, R.C. et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a COX-2-selective inhibitor. Arthritis Rheum 1998, 41(Suppl.): S93.
30. Simon, L.S., Lanza, F.L., Lipsky, P.E. et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum 1998, 41: 1591-602.
31. Geis, G.S., Hubbard, R., Callison, D., Yu, S., Zhao, W. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998, 41(Suppl.): S364.
32. Geis, G.S., Stead, H., Morant, S., Naudin, R., Hubbard, R. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 1998, 41(Suppl.): S216.
33. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986, 256: 1749-57.
34. Lim, H., Paria, B.C., Das, S.K. et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997, 91: 197-208.
35. Smith, G., Roberts, R., Hall, C. et al. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Br J Rheumatol 1996, 35: 458-62.
36. Zhao, S.Z., Hatoum, H.T., Hubbard, R.C. et al. Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. Arthritis Rheum 1997, 40(Suppl.): S88.
37. Hubbard, R., Geis, G.S., Woods, E., Yu, S., Zhao, W. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum 1998, 41(Suppl.): S196.
38. Saag, K., Fisher, C., McKay, J. et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. Arthritis Rheum 1998, 41(Suppl.): S196.
39. Cannon, G., Caldwell, J., Holt, P. et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum 1998, 41(Suppl.): S196.
40. Lane, N. Pain management in osteoarthritis: The role of COX-2 inhibitors. J Rheumatol 1997, 24(Suppl. 49): 20-4.
41. Enrich, E., Mehilsch, D., Perkins, S. et al. Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain. Arthritis Rheum 1996, 39(Suppl.): S81.
42. Ehrich, E., Dallob, A., Van Hecken, A. et al. Demonstration of selective COX-2 inhibition by MK-966 in humans. Arthritis Rheum 1996, 39(Suppl.): S81.
43. Mengle-Gaw, L., Hubbard, R.C., Karim, A. et al. A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheum 1997, 40(Suppl.): S93.